Published in AIDS on February 15, 2002
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol (2010) 2.91
Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med (2012) 1.69
Mitochondrial dysfunction in distal axons contributes to human immunodeficiency virus sensory neuropathy. Ann Neurol (2010) 1.10
Viral load, clinical disease severity and cellular immune responses in primary varicella zoster virus infection in Sri Lanka. PLoS One (2008) 1.02
Neurologic complications of HIV-1 infection and its treatment in the era of antiretroviral therapy. Continuum (Minneap Minn) (2012) 0.95
Schwann cells as a therapeutic target for peripheral neuropathies. CNS Neurol Disord Drug Targets (2010) 0.92
Impact of long-term treatment with neurotoxic dideoxynucleoside antiretrovirals: implications for clinical care in resource-limited settings. HIV Med (2008) 0.87
Controlling Neuropathic Pain in HIV. Curr Infect Dis Rep (2004) 0.87
Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation. J Acquir Immune Defic Syndr (2014) 0.80
Over-reported peripheral neuropathy symptoms in a cohort of HIV infected and uninfected Rwandan women: the need for validated locally appropriate questionnaires. Afr Health Sci (2014) 0.79
Microglial content-dependent inhibitory effects of calcitonin gene-related peptide (CGRP) on murine retroviral infection of glial cells. J Neuroimmunol (2015) 0.79
Is HIV Painful? An Epidemiologic Study of the Prevalence and Risk Factors for Pain in HIV-infected Patients. Clin J Pain (2014) 0.77
The reliability of the modified lower extremity functional scale among adults living with HIV on antiretroviral therapy, in Rwanda, Africa. SAHARA J (2014) 0.77
Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels, by Simpson et al. AIDS (2003) 0.75
Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS (2006) 7.99
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS (2007) 5.18
The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS (2005) 4.48
Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys (2009) 4.23
HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol (2002) 4.20
Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr (2010) 4.20
Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep (2010) 3.80
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med (2008) 2.96
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol (2010) 2.91
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet (2002) 2.36
Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology (2012) 2.30
Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg (2004) 2.29
Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol (2006) 2.27
The feasibility of voluntary counselling and HIV testing for pregnant women using community volunteers in Zimbabwe. Int J STD AIDS (2005) 2.27
A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis (2005) 2.25
Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bull World Health Organ (2010) 2.21
The OpenMRS Implementers Network. Int J Med Inform (2009) 2.19
Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis (2004) 2.17
Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med (2011) 2.17
Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda. J Acquir Immune Defic Syndr (2013) 2.15
Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol (2009) 2.14
Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg (2007) 2.10
Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS (2007) 2.09
Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis (2011) 2.08
Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS (2011) 2.04
Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neurovirol (2010) 1.95
An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol (2007) 1.94
Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med (2005) 1.93
The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain (2004) 1.90
Outcomes of HIV-infected orphaned and non-orphaned children on antiretroviral therapy in western Kenya. J Acquir Immune Defic Syndr (2006) 1.87
Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol (2004) 1.87
Outcomes of HIV-exposed children in western Kenya: efficacy of prevention of mother to child transmission in a resource-constrained setting. J Acquir Immune Defic Syndr (2010) 1.86
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther (2012) 1.79
Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol (2004) 1.79
Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infected patients on antiretroviral therapy in Africa. Trop Med Int Health (2010) 1.75
Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. J Infect Dis (2002) 1.70
Ordered multiple-class ROC analysis with continuous measurements. Stat Med (2004) 1.65
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med (2006) 1.65
Retention in care and connection to care among HIV-infected patients on antiretroviral therapy in Africa: estimation via a sampling-based approach. PLoS One (2011) 1.65
HIV-associated sensory neuropathies. AIDS (2002) 1.65
Evaluating sleep and cognition in HIV. J Acquir Immune Defic Syndr (2013) 1.64
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology (2013) 1.62
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol (2011) 1.57
Clinical validation of the NeuroScreen. J Neurovirol (2005) 1.57
HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS (2010) 1.56
Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read (2002) 1.56
A combination of the IPAG questionnaire and PiKo-6® flow meter is a valuable screening tool for COPD in the primary care setting. Prim Care Respir J (2011) 1.55
Peripheral neuropathy in HIV: prevalence and risk factors. AIDS (2011) 1.53
Genetic correlates of efavirenz hypersusceptibility. AIDS (2004) 1.50
The need for double-sampling designs in survival studies: an application to monitor PEPFAR. Biometrics (2008) 1.50
Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology (2004) 1.49
Diagnostic utility of the subjective peripheral neuropathy screen in HIV-infected persons with peripheral sensory polyneuropathy. AIDS Read (2005) 1.46
Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.46
Low atazanavir concentrations in cerebrospinal fluid. AIDS (2009) 1.45
The impact of the President's Emergency Plan for AIDS Relief on expansion of HIV care services for adult patients in western Kenya. AIDS (2009) 1.44
Quantitative MR spectroscopic imaging of brain lesions in patients with AIDS: correlation with [11C-methyl]thymidine PET and thallium-201 SPECT. Acad Radiol (2002) 1.43
Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J Virol (2008) 1.40
High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol (2003) 1.40
HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS (2006) 1.40
Regional patterns of brain metabolites in AIDS dementia complex. Neuroimage (2004) 1.40
Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity. J Neuropsychiatry Clin Neurosci (2007) 1.39
Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study. Leuk Res (2004) 1.39
Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol (2003) 1.39
Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology (2005) 1.39
Comparison of Three Screening Questionnaires for Chronic Obstructive Pulmonary Disease in the Primary Care. Respiration (2017) 1.38
Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives? J Int AIDS Soc (2011) 1.36
A multi-center 1H MRS study of the AIDS dementia complex: validation and preliminary analysis. J Magn Reson Imaging (2003) 1.34
Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol (2006) 1.33
Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr (2005) 1.32
Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. J Neurovirol (2011) 1.31
Retention of HIV-infected and HIV-exposed children in a comprehensive HIV clinical care programme in Western Kenya. Trop Med Int Health (2010) 1.31
Quantification of accuracy and precision of multi-center DTI measurements: a diffusion phantom and human brain study. Neuroimage (2011) 1.30
Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr (2003) 1.30
A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys (2009) 1.29
HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Res Hum Retroviruses (2002) 1.29
Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV. J Int Neuropsychol Soc (2008) 1.26
Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings. J Acquir Immune Defic Syndr (2010) 1.25
A causal framework for understanding the effect of losses to follow-up on epidemiologic analyses in clinic-based cohorts: the case of HIV-infected patients on antiretroviral therapy in Africa. Am J Epidemiol (2012) 1.24
Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. J Int AIDS Soc (2011) 1.24
Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS. J Neurovirol (2005) 1.23
Cerebral metabolite abnormalities in human immunodeficiency virus are associated with cortical and subcortical volumes. J Neurovirol (2010) 1.22
HIV-associated opportunistic infections of the CNS. Lancet Neurol (2012) 1.22
Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia. J Immunol (2007) 1.22